The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice
Fig 5
Intraperitoneal treatment with imatinib reduces MSU crystal-induced ankle inflammation in a therapeutic protocol.
(A) C57BL/6J mice received imatinib (100 mg/kg, i.p.) or vehicle (PBS) 1 and 6 h after i.a. injection of MSU crystals (0.5 mg in 10 μl) in one ankle and vehicle (10 μl PBS) in the contra-lateral ankle. (B) Time course of MSU crystal-induced ankle swelling in this therapeutic protocol (n = 8-9/group). Data are shown as means ± SEM of data pooled from the three independent experiments performed. *** = P < 0.001 vs. indicated group by repeated measures two-way ANOVA. (C) H&E-stained sections of ankle showing MSU injection sites 24 h after injection of 0.5 mg MSU crystals in the therapeutic protocol. Lower panels in C are enlargement of the areas marked (*) in the upper panels. Original magnification: x20.